

Research

Open Access

Changes in the total leukocyte and platelet counts in Papuan and non Papuan adults from northeast Papua infected with acute *Plasmodium vivax* or uncomplicated *Plasmodium falciparum* malaria

Walter RJ Taylor*^{1,2}, Hendra Widjaja¹, Hasan Basri¹, Colin Ohrt³, Taufik Taufik⁴, Emiliana Tjitra⁵, Samuel Baso⁶, David Fryauff¹, Stephen L Hoffman⁷ and Thomas L Richie¹

Address: ¹The US Navy Medical Research Unit no. 2, Jakarta, Indonesia, ²Dept. of Tropical Medicine, Tulane University School of Public Health, New Orleans, USA, ³Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington DC, USA, ⁴Indonesian Naval Hospital, Jayapura, Papua, ⁵Centre for Health Research and Development, National Institutes of Health, Jakarta, Indonesia, ⁶Rumah Sakit Umum, Jayapura, Papua, Indonesia and ⁷Naval Medical Research Center, Bethesda, Maryland, USA

Email: Walter RJ Taylor* - btaylor@oucr.org; Hendra Widjaja - Hwidjaja@fhi.or.id; Hasan Basri - Hbasri@fhi.or.id; Colin Ohrt - Cohrt@wrair.mil.gov; Taufik Taufik - Taufik@yahoo.com; Emiliana Tjitra - emilt@litbang.depkes.go.id; Samuel Baso - Sbaso@yahoo.com; David Fryauff - FryauffD@NMRC.NAVY.MIL; Stephen L Hoffman - slhoffman@sanaria.com; Thomas L Richie - RichieT@NMRC.NAVY.MIL

* Corresponding author

Published: 18 December 2008

Received: 1 September 2007

Malaria Journal 2008, **7**:259 doi:10.1186/1475-2875-7-259

Accepted: 18 December 2008

This article is available from: <http://www.malariajournal.com/content/7/1/259>

© 2008 Taylor et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: There are limited data on the evolution of the leukocyte and platelet counts in malaria patients.

Methods: In a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against *Plasmodium vivax* (n = 64) or *Plasmodium falciparum* (n = 98) malaria, the total white cell (WCC) and platelet (PLT) counts were measured on Days 0, 3, 7 and 28 in 57 indigenous Papuans with life long malaria exposure and 105 non Papuan immigrants from other parts of Indonesia with limited malaria exposure.

Results: The mean Day 0 WCC (n = 152) was 6.492 (range 2.1–13.4) × 10⁹/L and was significantly lower in the Papuans compared to the non Papuans: 5.77 × 10⁹/L vs. 6.86 × 10⁹/L, difference = -1.09 [(95% CI -0.42 to -1.79 × 10⁹/L), P = 0.0018]. 14 (9.2%) and 9 (5.9%) patients had leukopenia (<4.0 × 10⁹/L) and leukocytosis (>10.0 × 10⁹/L), respectively. By Day 28, the mean WCC increased significantly (P = 0.0003) from 6.37 to 7.47 × 10⁹/L (73 paired values) and was similar between the two groups. Ethnicity was the only WCC explanatory factor and only on Day 0.

The mean Day 0 platelet count (n = 151) was 113.0 (range 8.0–313.0) × 10⁹/L and rose significantly to 186.308 × 10⁹/L by Day 28 (P < 0.0001). There was a corresponding fall in patient proportions with thrombocytopenia (<150 × 10⁹/L): 119/151 (78.81%) vs. 16/73 (21.92%, P < 0.00001). Papuan and non Papuan mean platelet counts were similar at all time points. Only malaria species on Day 0 was a significant platelet count explanatory factor. The mean D0 platelet counts were significantly lower (P = 0.025) in vivax (102.022 × 10⁹/L) vs. falciparum (122.125 × 10⁹/L) patients.

Conclusion: Changes in leukocytes and platelets were consistent with other malaria studies. The Papuan non Papuan difference in the mean Day 0 WCC was small but might be related to the difference in malaria exposure.

Background

The malaria induced changes in the total white cell (WC) and platelet (PLT) counts have been documented in several clinical series of vivax and falciparum malaria in malaria immune and naïve patients of all ages [1-9], describing mostly the WC and PLT counts at presentation.

The majority of malaria patients at presentation have total WCCs in the normal range. Leukopaenia may affect up to 15% (WCC < $4 \times 10^9/L$) of malaria infected adults [3,4,8,10] and was present in ~10% of 1,369 hospitalized Kenyan children with moderately severe or severe falciparum malaria (WCC < $6.1 \times 10^9/L$) [6]. Rates of leukocytosis (> $10 \times 10^9/L$) in adults range between 1 and ~7% [1,3,4,9,11,12] and was 20% in the hospitalized Kenyan children (> $16.5 \times 10^9/L$) [6]. Reported, malaria induced changes in the differential white cell counts include neutropaenia, neutrophilia, immature neutrophils (left shift), neutrophil toxic granulation, lymphopaenia, lymphocytosis, atypical lymphocytes, monocytosis, eosinopaenia, post treatment eosinophilia, and leukaemoid reactions [3-5,10,11,13-19]. The underlying mechanisms include a shift in neutrophils from the circulatory to the marginal pool to sites of inflammation, splenic localisation, serum lymphotoxic factors, and intercurrent bacterial infections [13,15,20-23]. In experimentally induced falciparum malaria, Aotus monkeys had an increase in the absolute neutrophil counts seven days post infection that was followed by neutropaenia by Day 14; the reverse was found for the lymphocyte counts [24]. Ethnicity, sex and immune status may also be relevant factors affecting the leukocyte count. Leukocytosis was more common in *Plasmodium vivax* infected African American soldiers (27%) compared to Caucasian soldiers (9%) but the latter had higher rates (47 vs. 26%) of relative lymphocytosis (lymphocyte count > 35%) [14]. Studies in temperate climates have found that individuals of African origin tend to have lower total leukocyte, neutrophil and platelet counts compared to Caucasians and women have higher leukocyte and neutrophil counts than men [25,26]. Malaria naïve Sri Lankans infected with *P. vivax* had higher mean lymphocyte counts and significantly raised gamma/delta T cells during fever paroxysms compared to malaria immune vivax patients, suggesting a greater inflammatory response by the non immune patients [27]. Similarly, TNF α levels were greater in non immune Sri Lankans with *P. vivax* [28].

Studies examining trends in the total WCC are few. One study of experimentally induced falciparum malaria in non immune Americans showed an initial fall in the mean WCC reaching a nadir on Day 3 and rising thereafter to baseline values by study end [2]. Studies in African children have shown modest falls in the mean total WCC over 7 to 14 days whilst another study found that acutely

ill falciparum infected children had a significant fall in the mean neutrophil count on Day 3 [29-31].

Malaria induced thrombocytopenia (platelet count < $150 \times 10^9/L$) is very common, affecting between 40–85% of patients [4,7-9,32-35]. Moderate ($50-100 \times 10^9/L$) and severe (< $50 \times 10^9/L$) thrombocytopenia occur in 30–50 and 6–16%, respectively [4,5,7,30,35]. Thrombocytopenia improves with disease resolution and the platelet count is generally normal within seven days [34,35] but ranged from 2–28 days in one series [35]. Considerable overlap exists between the platelet counts of the different malaria species and between uncomplicated and severe falciparum malaria. Two studies suggest that a lower platelet count may be an indicator of higher biomass falciparum and vivax infections [36,37] but Eriksson *et al* did not find this correlation [4]. Factors associated with malaria induced thrombocytopenia include splenomegaly, splenic sequestration and platelet removal by macrophages [38-40]. The role of antiplatelet antibodies is unclear [34,41,42].

In north east Papua, indigenous Papuans have life long exposure to malaria whereas Indonesians who immigrate to Papua usually contract malaria for the first time in Papua [43]. Whether this difference in malaria exposure affects the white cell and platelet counts in diseased patients is unknown. This paper presents data from a clinical trial on the evolution of the total white cell and platelet counts and explores possible Papuan non Papuan differences.

Materials and methods

Malariometric data from this area of northeast Papua and study conduct are detailed elsewhere [44,45]. Briefly, indigenous adult Papuans (n = 57) and non Papuan (n = 105) adults from other parts of Indonesia were recruited into a hospital based, 28 days, clinical trial comparing chloroquine vs. chloroquine plus doxycycline vs. doxycycline for the treatment of parasitologically proven (Giemsa stained thick and thin blood films) acute uncomplicated falciparum and acute vivax malaria. There was no minimum parasitaemia for either species but a maximum of 150,000/ μL asexual falciparum forms/ μL for study entry. Recruited patients underwent a history, a detailed physical examination (including an abdominal examination to detect hepatosplenomegaly) and supervised treatment. Giemsa stained blood films were taken and read on Days 0–7, 14, 21, 28 and a blood count (Hb, total WCC, platelet count) was performed on Days 0, 3, 7, and 28; a manual differential white cell count was not done. Double entered, validated data were analysed using Epi Info 6.04b (Centers for Disease Control and Prevention, Atlanta, GA, USA) and Stata v 8 (Stata Corporation, USA). Normally distributed data were compared using the stu-

dent's 't' test or ANOVA or the Mann-Whitney U or Kruskal-Wallis for skewed data. Spearman's rank correlation was used to determine the relationship between skewed continuous data. Proportions were compared using uncorrected chi squared values. Multivariate analyses were performed to assess the independence of ethnicity, splenomegaly, gender, malaria species and drug regimen on the total white cell and platelet counts. A P value of ≤ 0.05 was considered significant; no adjustment was made for multiple comparisons. Written informed consent was obtained from all patients. The study was conducted according to the Indonesian Ministry of Health, the Indonesian Navy, and the United States Navy and Army regulations governing the protection of human subjects.

Results

A total of 162 malaria infected patients were recruited into the study: *P. vivax* (n = 63), *P. falciparum* (n = 89), and mixed infections (n = 10). Based on the dominant species, the 10 mixed infections were reclassified as vivax (n = 1) or falciparum (n = 9) malaria. Males (aged 15 to 44), numbered 146 (~90%), and women (aged 15 to 33) 16 (~10%). The Papuans numbered 57; the 105 non Papuans came from Java (n = 54), Sulawesi (n = 28), Ambon (n = 9), Bali (n = 7), Sumatera (n = 5), and other islands (n = 2). Median Papuan and non Papuan [interquartile (IQ) range] residential times in Papua were 21.5 (18 to 24) and three (1 to 5) years, respectively (P < 0.0001). 152/162 (93.8%) had blood results available for Day 0 and 74 patients completed the study to Day 28. Splenomegaly was more common in the Papuans, 26/57 (45.6%), compared to the non Papuans, 27/105 (25.7%),

for a relative risk of 1.8 [95% confidence interval (CI) 1.15 to 2.7].

Day 0 total white cell counts

The Day 0 total WCCs ranged from 2.1–13.4 $\times 10^9/L$ with a median and mean of 6.3 and 6.492 $\times 10^9/L$, respectively. Leukopaenia (WCC < 4 $\times 10^9/L$) was present in 14 patients (9.2%); their WCCs ranged from 2.1–3.9 $\times 10^9/L$. Nine (5.9%) patients had a leukocytosis (WCC > 10 $\times 10^9/L$). Thus, the majority of patients, ~85%, had a normal total WCC at presentation. In the multivariate analysis, only ethnicity was a significant explanatory variable for the total WCC on Day 0. The mean Day 0 total WCC was significantly lower in the Papuans (5.7 $\times 10^9/L$) compared to the non Papuans (6.8 $\times 10^9/L$): difference = -1.09 [(95% CI -0.42 to -1.79 $\times 10^9/L$), P = 0.0018]. There was a positive correlation between the Day 0 WCC and the *P. vivax* parasitaemia (Sp rho = 0.43, P = 0.0003) but no correlation between the Day 0 WCCs and: (i) the Day 0 falciparum counts [Spearman's (Sp) rho = 0.139, P = 0.19], (ii) the Day 0 temperature (Sp rho = -0.0066, P = 0.94), and (iii) the Day 0 platelet count (Sp rho = 0.125, P = 0.12).

Evolution of the total white cell counts

The changes in the mean white cell counts during follow up were similar for both malaria species and ethnic groups (Figures 1 and 2). Compared to baseline, the fall in the mean total WCC on Day 3 was significant in the non Papuans: (i) Pf: -0.898 (5.735 – 6.633) $\times 10^9/L$ (P = 0.0015), (ii) Pv: -1.069 (6.132 – 7.201) $\times 10^9/L$ (P = 0.0012). The mean Day 3 Day 0 difference between the non Papuans and Papuans was also significantly different




Figure 1
The mean (95% CI) total white cell counts in falciparum infected Papuan and non Papuan patients.




Figure 2
The mean (95% CI) total white cell counts in vivax infected Papuan ($5.66 \times 10^9/L$) and non Papuan ($7.20 \times 10^9/L$) patients. The mean difference at baseline is $-1.54 (-0.47 \text{ to } -2.62) \times 10^9/L$, $P = 0.0055$].

[Pf: -0.898 vs. $0.248 \times 10^9/L$ ($P = 0.008$), Pv: -1.069 vs. $0.626 \times 10^9/L$ ($P = 0.0054$)].

By Day 28, the number of evaluable patients had fallen to 74. The mean total WCC was: (i) significantly higher compared to baseline ($n = 73$ pairs) 7.47 vs. $6.37 \times 10^9/L$: difference = $1.1 (0.52 - 1.69) \times 10^9/L$, $P = 0.0003$] and (ii) similar between the Papuans [$7.79 \times 10^9/L$ ($n = 27$)] and the non Papuans [$7.3 \times 10^9/\mu L$ ($n = 47$)] but there was a trend towards a higher mean change in the Papuans compared to the non Papuans: 1.8 vs. $0.7 \times 10^9/L$ ($P = 0.07$). There was no Day 28 leukopaemia but five (6.7%) patients had leukocytosis. Their Day 28 Day 0 matching values ($\times 10^9/L$) were: $10.4-3.4$, $10.8-6$, $12-7.2$, $12.2-9.2$, $16.4-7$. They were all aparasitaemic, afebrile, and discharged clinically well from the hospital.

Day 0 platelet counts

The Day 0 platelet counts (PLT0) for all patients combined varied widely, ranging from $8-313 \times 10^9/L$ (IQ range 76 to $141 \times 10^9/L$); the median and mean values were 102 and $113 \times 10^9/\mu L$, respectively. The majority of patients, $119/151$ (78.8%), had thrombocytopenia ($<150 \times 10^9/L$); 43.7% ($66/151$) had moderate thrombocytopenia ($50-100 \times 10^9/L$). Five *P. falciparum* and eight had *P. vivax* (8.6%) infected patients were severely thrombocytopenic ($<50 \times 10^9/\mu L$) but none had clinical signs of bleeding. Of the 88 patients who had urine dipstick tests, nine (10.2%) had microscopic haematuria (vivax = 4, falciparum = 5); the platelet counts in these nine ranged from $50-313$ (median 101) $\times 10^9/L$.

The multivariate analysis showed that only the malaria species was a significant independent variable to explain the Day 0 platelet count. The mean PLT0 was significantly lower ($P = 0.025$) in the vivax patients: 102.022 vs. $122.125 \times 10^9/L$. The PLT0 was negatively correlated with the Day 0 falciparum parasitaemia (Sp rho = -0.29 , $P = 0.005$) but not with the Day 0 vivax parasitaemia (Sp rho = -0.0984 , $P = 0.4$). There was also a significant negative correlation with the Day 0 temperature (Sp rho = -0.21 , $P = 0.009$) and the PLT0 in the vivax patients (Sp rho = -0.26 , $P = 0.04$) and a negative trend in falciparum patients (Sp rho = -0.18 , $P = 0.097$).

Evolution of the platelet counts

The proportion of thrombocytopenic patients declined over time: 78.8% ($119/151$) on D0, 74.26% ($101/136$) on D3, 23.62% ($30/127$) on D7 and 21.92% ($16/73$) on Day 28 ($P < 0.0001$, χ^2 for trend). By Day 28, the mean platelet count was significantly higher compared to baseline: 188.308 vs. $108.056 \times 10^9/L$ ($P < 0.0001$), and ranged from 47.0 to 318.2 (IQ range 153 to 226) $\times 10^9/L$ (Figures 3, 4 and 5). The mean D28-D0 changes in platelet counts were not significantly different between the Papuans and non Papuans: 83.280 vs. $75.576 \times 10^9/L$ ($P = 0.6$). The mean Day 7 platelet count was significantly higher than that of Day 28 only in the vivax infected non Papuans ($n = 21$): 175.819 vs. $251.238 \times 10^9/L$ ($P = 0.0036$). The multivariate analyses were unremarkable, except for drug arm as a PLT7 explanatory factor. This was accounted for by the combination vs. the doxycycline arm: 235.463 vs. $191.741 \times 10^9/L$ ($P = 0.029$).




Figure 3
Mean (95% CI) platelet counts of malaria infected Papuans and non Papuans as a function of a palpable spleen.

Discussion

These analyses have shown that at presentation the majority of malaria infected patients had total white cell counts within the normal range and most were thrombocytopaenic. By Day 28, both mean counts had increased but thrombocytopaenia remained in just over 20% of patients. These data complement and are broadly consistent with those of other clinical series.

Data from this study were from two dissimilar groups with respect to ethnicity and the degree of malaria acquired immunity. The Papuans had life long malaria exposure whilst the non Papuans had limited or no malaria exposure. The Papuans had lower mean Day 0 white counts than the non Papuans and there was a notable difference in the WCC changes over time. They rose steadily in the Papuans but fell significantly on Day 3 in the non Papuans, consistent with a study of experimen-




Figure 4
The mean (95% CI) platelet counts in falciparum infected Papuan and non Papuan patients.




Figure 5
The mean (95% CI) platelet counts in vivax infected Papuan and non Papuan patients.

tally induced falciparum malaria in malaria naïve American volunteers [2]. By Day 28, the mean WCCs in the non Papuans had caught up and both groups had similar mean WCCs. This difference in the WCC progressions between the two ethnic groups is difficult to explain purely on the basis of a redistribution of white cells and/or splenic sequestration, given that the malaria naïve non Papuans had significantly less splenomegaly. These data might indicate that a lesser degree of malaria exposure, thus acquired immunity, in the non Papuans resulted in a more robust inflammatory response, reflected crudely by a higher, baseline total WCC [27]. The initial fall in the total WCC in the non Papuans might reflect a difference in response to dying parasitized red cells consequent to treatment.

Thrombocytopenia was common at presentation in both groups of patients. There were no differences between the Papuans and non Papuans but the mean platelet count was lower in vivax compared to falciparum infected patients. There were negative correlations between the Day 0 platelet count and the falciparum parasite count and the Day 0 temperature in the vivax patients. These findings are consistent with some but not other reports and are of limited clinical value [2,4,8,31,34]. Over time, the mean platelet count increased, consistent with the findings of others but two reports document an initial fall in the platelet count followed by recovery [2,4]. The mean platelet count appeared higher on Day 7 compared to Day 28 but there are no intervening platelet counts, so the day

of the mean peak platelet count cannot be determined. Some 20% of patients were still thrombocytopenic by study end, suggesting a number of patients need longer than four weeks for full platelet recovery. The multivariate analysis found drug arm to be significant factor for the Day 7 platelet count with the combination arm having a higher mean platelet count than the doxycycline arm. This is of little clinical significance.

Our study had limitations. The study sample was small and powered for a clinical trial. The data presented were secondary analyses to look for possible Papuan non Papuan differences. Many patients failed treatment before Day 28, given rescue treatment and withdrawn from the study; this may have introduced a statistical bias. Most patients were male, thus limiting the applicability of the findings. There were many statistical comparisons and some significant results may have occurred by chance. The differential white cell count was not measured and could have provided additional interesting data.

Conclusion

To conclude, these analyses have compared and contrasted the changes in the total white cell and platelet counts in Papuans and non Papuans with different degrees of malaria exposure that may partly explain the difference in the mean total white cell count at presentation between the two groups.

Authors' contributions

WRJT, the principal investigator, developed the protocol, supervised study execution, analysed the data and wrote the first draft of the paper. CO conceived the study, developed the protocol and critically reviewed the manuscript. ET developed the protocol, was involved in study execution and critically reviewed the manuscript. SLH developed the protocol and critically reviewed the manuscript. TLR developed the protocol and critically reviewed the manuscript. HW played a key role in study execution and reviewed the manuscript. HB was involved in study execution and reviewed the manuscript. Taufik was involved in study execution and reviewed the manuscript. SB was involved in study execution and reviewed the manuscript. DF was involved in data interpretation and critically reviewed the manuscript.

Acknowledgements

The authors wish to thank the following for their contribution to the study: (i) the nurses at the Jayapura General hospital and the Indonesian Navy hospital (ii) Drs. Oyong (Jayapura General Hospital), Subianto, (Provincial Health Office, Jayapura), and Kristanto (Indonesian Naval Hospital, Jayapura) for their support in study execution, (iii) Nona Nurjaya and Pak Ferry for slide reading, laboratory work, and data management, (iv) Pak Purnomo, Pak Sofyan, Awalludin and Suradi for slide reading.

This study was funded by the US Naval Medical Research and Development Command (DoD 63002A M00101 HEX 2406)

The views expressed in this paper are the authors' and do not in any way represent those of the Indonesian Navy, the Indonesian Ministry of Health, or the US Navy.

References

- Martelo OJ, Smoller M, Saladin TA: **Malaria in American soldiers.** *Arch Intern Med* 1969, **123**:383-387.
- Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, Davis JR, Herrington DA, Clyde DF, Shmuklarsky MJ, Schneider I, McGovern TW, Chulay JD, Ballou WR, Hoffman SL: **Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge.** *J Infect Dis* 1997, **175**:915-920.
- Goldstein E: **A clinical study of falciparum and vivax malaria in Vietnam servicemen.** *Mil Med* 1968, **133**:991-6.
- Eriksson B, Hellgren U, Rombo L: **Changes in erythrocyte sedimentation rate, C-reactive protein, and haematological parameters in patients with acute malaria.** *Scand J infect Dis* 1989, **21**:435-41.
- Stein CM, Gelfand : **The clinical features and laboratory findings in acute Plasmodium falciparum malaria in Harare, Zimbabwe.** *Cent Afr J Med* 1985, **31**(9):166-170.
- Ladhani S, Lowe B, Cole AO, Kowuondo K, Newton CRJC: **Changes in white blood cells and platelets in children with falciparum malaria: relationship to disease outcome.** *Br J Haematol* 2002, **119**(3):839-847.
- Lynk A, Gold R: **Review of 40 children with imported malaria.** *Pediatr Infect Dis J* 1989, **8**:745-50.
- Svenson JE, MacLean JD, Gyorkos TW, Keystone J: **Imported malaria. Clinical presentation and examination of symptomatic travelers.** *Arch Intern Med* 1995, **155**:861-8.
- Winters RA, Murray HW: **Malaria – the mime revisited: fifteen years of experience at a New York city teaching hospital.** *Am J Med* 1992, **243**:243-6.
- Jadhav UM, Singhvi R, Shah R: **Prognostic implications of white cell differential count and white cell morphology in Malaria.** *J Postgrad Med* 2003, **49**:218-20.
- Reiley CG, Barrett O: **Leukocyte response in acute malaria.** *Am J Med Sci* 1971, **262**:153-8.
- Sharma SK, Das RK, Das BK, Das PK: **Haematological and coagulation profile in acute falciparum malaria.** *J Assoc Physicians India* 1992, **40**:581-3.
- Dale DC, Wolff : **Studies of the neutropenia of acute malaria.** *Blood* 1973, **41**:197-206.
- Fisher GU, Gordon MP, Lobel HO, Runcik K: **Malaria in soldiers returning from Vietnam.** *Am J Trop Med Hyg* 1970, **19**:27-39.
- Hviid L, Kemp K: **What is the cause of lymphopenia in malaria?** *Infect Immun* 2000, **68**:6087-9.
- Kueh YK, Yeo KL: **Haematological alterations in acute malaria.** *Scand J Haematol* 1982, **29**:147-52.
- Shanks GD, Wilairatanaporn C: **Eosinophilic response to falciparum malaria infections.** *Southeast Asian J Trop Med Public Health* 1992, **23**:795-7.
- Irving KG, Kemp E, Olivier BJ, Mendelow BV: **Unusual presentation of malaria as a leukaemoid reaction.** *SAMJ* 1987, **71**:597-8.
- Camacho LH, Wilairatana P, Weiss G, Mercader MA, Brittenham GM, Looreesuan S, Gordeuk VR: **The eosinophilic response and haematological recovery after treatment for Plasmodium falciparum malaria.** *Trop Med Int Health* 1999, **4**:471-5.
- Playfair JHL, DeSouza JB: **Lymphocyte traffic and lymphocyte destruction in murine malaria.** *Immunology* 1982, **46**:125-33.
- Mabey DC, Brown A, Greenwood BM: **Plasmodium falciparum malaria and Salmonella infections in Gambian children.** *J Infect Dis* 1987, **155**:1319-21.
- Bordessoule D, Gaulard P, Mason DY: **Preferential localisation of human lymphocytes bearing gamma delta T cell receptors to the red pulp of the spleen.** *J Clin Pathol* 1990, **43**:461-4.
- Langhorne J, Simon-Haarhaus B: **Differential T cell responses to Plasmodium chabaudi chabaudi in peripheral blood and spleens of C57BL/6 mice during infection.** *J Immunol* 1991, **146**:2771-5.
- Kakoma I, James MA, Whiteley HE, Montelegrè F, Buesè M, Fajfar-Whestone CJ, Clabaugh GW, Baek BK: **Platelet kinetics and other hematological profiles in experimental Plasmodium falciparum infection: a comparative study between Saimiri and Aotus monkeys.** *Kisaengchunghak Chapchi* 1992, **30**:177-82.
- Freedman DS, Gates L, Flanders WD, Van Assendelft OW, Barboriak JJ, Joesoef MR, Byers T: **Black/white differences in leukocyte subpopulations in men.** *Int J Epidemiol* 1997, **26**:757-64.
- Bain BJ: **Ethnic and sex differences in the total and differential white cell count and platelet count.** *J Clin Pathol* 1996, **49**:664-6.
- Perera MK, Carter R, Goonewardene R, Mendis KN: **Transient increase in circulating gamma/delta T cells during Plasmodium vivax malarial paroxysms.** *J Exp Med* 1994, **179**:311-5.
- Karunaweera ND, Carter R, Grau GE, Mendis KN: **Demonstration of anti-disease immunity to Plasmodium vivax malaria in Sri Lanka using a quantitative method to assess clinical disease.** *Am J Trop Med Hyg* 1998, **58**:204-10.
- Penali LK, Assi-Coulibaly L, Kaptue B, Konan D, Ehouman A: **Parasitological and clinical response to amodiaquine versus chloroquine in the treatment of Plasmodium falciparum malaria in children in an endemic area.** *Bull Soc Pathol Exot* 1994, **87**:244-7.
- Staedke SG, Kanya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ: **Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial.** *Lancet* 2001, **358**:368-74.
- Abdalla SH: **Peripheral blood and bone marrow leucocytes in Gambian children with malaria: numerical changes and evaluation of phagocytosis.** *Ann Trop Paed* 1988, **8**(4):250-258.
- Newton JA, Schnepf GA, Wallace MR, Lobel HO, Kennedy CA, Oldfield EC: **Malaria in US marines returning from Somalia.** *JAMA* 1994, **272**(5):397-399.
- Oh MD, Shin H, Shin D, Kim U, Lee S, Kim N, Choi MH, Chai JY, Choe K: **Clinical features of vivax malaria.** *Am J Trop Med Hyg* 2001, **65**:143-6.
- Looreesuan S, Davis JG, Allen DL, Lee SH, Bunnag D, White NJ: **Thrombocytopenia in malaria.** *Southeast Asian J Trop Med Public Health* 1992, **23**(1):44-50.
- Moulin F, Lesage F, Legros A-H, Maroga C, Moussavou A, Guyon P, Marc E, Gendrel D: **Thrombocytopenia and Plasmodium falciparum malaria in children with different exposures.** *Arch Dis Child* 2003, **88**:540-1.

36. Richards MW, Behrens RH, Doherty JF: **Short report: hematologic changes in acute, imported Plasmodium falciparum malaria.** *Am J Trop Med Hyg* 1998, **59**:859.
37. Erhart LM, Yingyuen K, Chuanak N, Buathong N, Laoboonchai A, Miller RS, Meshnick SR, Gasser RA Jr, Wongsrichanalai C: **Hematologic and clinical indices of malaria in a semi-immune population of western Thailand.** *Am J Trop Med Hyg* 2004, **70**:8-14.
38. Niazi GA: **Haematological aspect of malaria in a population based hospital, Saudi Arabia.** *J Egypt Soc Parasitol* 1995, **25**:787-93.
39. Skudowitz RB, Katz J, Lurie A, Levin J, Metz J: **Mechanisms of thrombocytopenia in malignant tertian malaria.** *BMJ* 1973, **2**:515-8.
40. Essien E: **The circulating platelet in acute malaria infection.** *B J Haematol* 1989, **72**:589-90.
41. Yamaguchi S, Kubota T, Yamagishi T, Okamoto K, Izumi T, Takada M, Kanou S, Suzuki M, Tsuchiya J, Naruse T: **Severe thrombocytopenia suggesting immunological mechanisms in two cases of vivax malaria.** *Am J Hematol* 1997, **56**:183-6.
42. Beale PJ, Cormack JD, Oldrey TBN: **Thrombocytopenia in malaria with immunoglobulin (IgM) changes.** *BMJ* 1972, **1**:34-9.
43. Baird JK, Jones TR, Danudrigo EW, Annis BA, Bangs MJ, Basri H, Purnomo , Masbar S: **Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria.** *Am J Trop Med Hyg* 1991, **45**:65-76.
44. Taylor WR, Widjaja H, Richie TL, Basri H, Ohrt C, Tjitra , Taufik E, Jones TR, Kain KC, Hoffman SL: **Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia.** *Am J Trop Med Hyg* 2001, **64**:223-8.
45. Jones TR, Baird K, Bangs MJ, Annis BA, Purnomo , Basri H, Gunawan S, Harjosuwarno S, McElroy PD, Hoffman SL: **Malaria vaccine study site in Irian Jaya, Indonesia: Plasmodium falciparum incidence measurements and epidemiological considerations in sample size estimation.** *Am J Trop Med Hyg* 1994, **50**:210-18.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

